We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Edwards Lifesciences Corp (EW) Com Stk USD1

Sell:$65.83 Buy:$65.85 Change: $0.16 (0.24%)
Market closed |  Prices as at close on 7 November 2024 | Switch to live prices |
Sell:$65.83
Buy:$65.85
Change: $0.16 (0.24%)
Market closed |  Prices as at close on 7 November 2024 | Switch to live prices |
Sell:$65.83
Buy:$65.85
Change: $0.16 (0.24%)
Market closed |  Prices as at close on 7 November 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.

Contact details

Address:
One Edwards Way
IRVINE
92614
United States
Telephone:
+1 (949) 2502500
Website:
https://www.edwards.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EW
ISIN:
US28176E1082
Market cap:
$39.61 billion
Shares in issue:
602.40 million
Sector:
Health Care Equipment
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Bernard Zovighian
    President, Chief Executive Officer
  • Scott Ullem
    Chief Financial Officer, Corporate Vice President
  • Wayne Markowitz
    Senior Vice President, General Manager - Surgical Structural Heart
  • Donald Bobo
    Corporate Vice President - Strategy and Corporate Development
  • Daveen Chopra
    Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
  • Jean-Luc Lemercier
    Corporate Vice President, EMEACLA (Europe, Middle East, Africa, Canada and Latin America)
  • Daniel Lippis
    Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)
  • Catherine Szyman
    Corporate Vice President - Critical Care
  • Larry Wood
    Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.